Cancer BiologybioRxivPreprint
HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.
Xiaoqing Cheng, Jacob Hsia, Jesus Iraheta…·Ron Bose
This study shows that HER2 and TP53 co-mutant cancers have increased histone acetylation and are sensitive to neratinib plus trastuzumab deruxtecan.
DOI 10.1101/2025.07.06.663368